C21 InvestmentsCXXIF +10.72%31 EV-to-FCF is 35.38 as of Jul. 03, 2026, which is 278% above its 10-year median of 9.35. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 561 Drug Manufacturers companies, C21 Investments ranks worse than 63.64% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, C21 Investments's Enterprise Value is $39.28 Mil.
C21 Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1.11 Mil. Therefore, C21 Investments's EV-to-FCF for today is 35.38.
The historical rank and industry rank for C21 Investments's EV-to-FCF or its related term are showing as below:
CXXIF'
s EV-to-FCF Range Over the Past 10 Years
Min: -49.46 Med: 9.35 Max: 65.45
Current: 35.38
During the past 13 years, the highest EV-to-FCF of C21 Investments was 65.45. The lowest was -49.46. And the median was 9.35.
CXXIF's EV-to-FCF is ranked worse than 63.64% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs CXXIF: 35.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C21 Investments's PE Ratio (TTM) for today is calculated as:
C21 Investments's share price for today is $0.2437.
C21 Investments's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
C21 Investments EV-to-FCF Related Terms
C21 Investments EV-to-FCF Historical Data
* Premium members only.
The historical data trend for C21 Investments's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where C21 Investments's EV-to-FCF falls into.
C21 Investments's current Enterprise Value is $39.28 Mil.
C21 Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a EV-to-FCF of 35.38 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C21 Investments and its competitors. This is 278% above median its historical median of 9.35. According to the industry distribution chart, C21 Investments ranks #357 out of 561 companies in the Drug Manufacturers industry, placing it in the top 63.6%.
Is C21 Investments' EV-to-FCF too high?
C21 Investments' current EV-to-FCF of 35.38 is 278% above median its 10-year median of 9.35. The Drug Manufacturers industry median EV-to-FCF is 20.16. C21 Investments' value of 35.38 is 75.5% above this industry median. Based on the distribution chart, C21 Investments ranks #357 out of 561 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #357 out of 561 companies for EV-to-FCF. This places C21 Investments in the lower half of its industry. The industry median EV-to-FCF is 20.16. C21 Investments' value of 35.38 is 75.5% above this benchmark. While the company's 10-year median is 9.35 vs. the industry median of 20.16, C21 Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current EV-to-FCF of 35.38 is 75.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current EV-to-FCF is 35.38, which is 278% above median its own 10-year median of 9.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.24 — trading 13% below its estimated fair value. The current EV-to-FCF is 35.38, which is 278% above median its 10-year median of 9.35 and 75.5% above the Drug Manufacturers industry median of 20.16. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For C21 Investments (CXXIF), the current EV-to-FCF is 35.38 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.24 is trading 13% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
EV-to-FCF: 35.38 (278% above median its 10-year median of 9.35)
GF Value™: $0.28 vs. price of $0.24 (13% below fair value)
Industry Position: 75.5% above the Drug Manufacturers median (#357 of 561)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
